Immunome Appoints Dr. Dennis Giesing as Chief Development Officer
– Pharmaceutical industry veteran brings more than three decades of experience developing innovative therapies –
News
Ride Health to Provide Non-Emergency Transportation for Complex Patient Populations Across New York State Through Partnership With IMSNY
Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
– IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing –
– IMM-ONC-01: Advanced proprietary antibody against IL-38 into IND-enabling studies –
– Raised $44.9 million in gross proceeds in NASDAQ IPO –
– Program updates expected in 2Q 2021 –
Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.
– Renovacor, Inc. has entered into a denitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) –
– Upon closing, the combined company is expected to receive up to $116 million in proceeds and is expected to be listed on NYSE under the ticker symbol “RCOR” –
– The business combination is expected to be completed in the second quarter of 2021 –
Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies
First oncology product candidate identified using the company’s human memory B-cell platform, and intended for potential treatment of solid tumors
ArchCare Delivers PACE Participants Seamless, Free Transportation
Technology-Based Ride System Will Serve 702 Home-Based Elderly
Annovis Bio Announces Positive Phase 2 Data – Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson’s Patients
Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate
VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021